drugset / Trial / NCT00003130
Paclitaxel in Treating Women With Recurrent Solid Tumors
Phase 2
Completed
32 enrolled
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating women who have recurrent solid tumors.
Timeline
- Start
- 1997-11
- Primary completion
- 2002-01
- Completion
- 2006-01
Publications
- Results Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004 Dec 15;10(24):8325-31. doi: 10.1158/1078-0432.CCR-04-1078.
- Results Miller AA, Rosner GL, Egorin MJ, et al.: Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/pharmacodynamics in women with solid tumors (CALGB 9763). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-500, 125, 2003.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 360 mg | Intravenous |